Home
ALLR
ALLR News

Latest Allarity Therapeutics Inc. (ALLR) News on August 3, 2025

Allarity Therapeutics Receives Australian Patent Acceptance Notice for Stenoparib DRP® Companion Diagnostic

GlobeNewswire

a month ago

Allarity Therapeutics Receives Australian Patent Acceptance Notice for Stenoparib DRP® Companion Diagnostic

Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer

GlobeNewswire

a month ago

Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer

Allarity Therapeutics Announces Changes to Board of Directors

GlobeNewswire

2 months ago

Allarity Therapeutics Announces Changes to Board of Directors

Allarity Therapeutics Announces Research Collaboration with Indiana Biosciences Research Institute to Further Advance Understanding of Stenoparib’s Unique, Dual Therapeutic Mechanism of Action

GlobeNewswire

2 months ago

Allarity Therapeutics Announces Research Collaboration with Indiana Biosciences Research Institute to Further Advance Understanding of Stenoparib’s Unique, Dual Therapeutic Mechanism of Action

Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer

GlobeNewswire

2 months ago

Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer

Allarity Therapeutics Announces Participation in Pharma Partnering Summit US

GlobeNewswire

3 months ago

Allarity Therapeutics Announces Participation in Pharma Partnering Summit US

Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment

GlobeNewswire

3 months ago

Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment

Allarity Therapeutics Presents Novel Drug Response Predictor—DRP®—for Daratumumab in Multiple Myeloma at AACR 2025

GlobeNewswire

3 months ago

Allarity Therapeutics Presents Novel Drug Response Predictor—DRP®—for Daratumumab in Multiple Myeloma at AACR 2025

Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business Update

GlobeNewswire

4 months ago

Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business Update

Allarity Therapeutics Launches Comprehensive Effort to Combat Potential Illegal Naked Short Selling of Its Shares

GlobeNewswire

4 months ago

Allarity Therapeutics Launches Comprehensive Effort to Combat Potential Illegal Naked Short Selling of Its Shares

Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in Advanced Ovarian Cancer Patients at the 2025 Annual Meeting for the Society of Gynecologic Oncology

GlobeNewswire

5 months ago

Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in Advanced Ovarian Cancer Patients at the 2025 Annual Meeting for the Society of Gynecologic Oncology

MT Newswires

5 months ago

Allarity Therapeutics Reaches Final Settlement With SEC Over Past Disclosures

Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission

GlobeNewswire

5 months ago

Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission

Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration

GlobeNewswire

5 months ago

Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration

Allarity Therapeutics Announces Board Authorization of $5 Million Share Repurchase Program

GlobeNewswire

5 months ago

Allarity Therapeutics Announces Board Authorization of $5 Million Share Repurchase Program

Allarity Therapeutics Announces Dismissal of Securities Class Action Lawsuit

GlobeNewswire

5 months ago

Allarity Therapeutics Announces Dismissal of Securities Class Action Lawsuit

Allarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer Patients

GlobeNewswire

5 months ago

Allarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer Patients

Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer

GlobeNewswire

6 months ago

Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer

Allarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC

GlobeNewswire

6 months ago

Allarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC

Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements

GlobeNewswire

9 months ago

Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements

Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational Highlights

GlobeNewswire

9 months ago

Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational Highlights

Allarity Therapeutics to be Granted European Patent for DRP® Companion Diagnostic for Stenoparib

GlobeNewswire

9 months ago

Allarity Therapeutics to be Granted European Patent for DRP® Companion Diagnostic for Stenoparib

Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement

GlobeNewswire

10 months ago

Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement

Allarity Therapeutics Strengthens Leadership with Key Appointments to Accelerate Stenoparib PARP Inhibitor Program

GlobeNewswire

10 months ago

Allarity Therapeutics Strengthens Leadership with Key Appointments to Accelerate Stenoparib PARP Inhibitor Program

Allarity Therapeutics Announces Two Patients Now Exceeding One Year of Treatment with Stenoparib in Advanced Ovarian Cancer Trial

GlobeNewswire

a year ago

Allarity Therapeutics Announces Two Patients Now Exceeding One Year of Treatment with Stenoparib in Advanced Ovarian Cancer Trial

MT Newswires

a year ago

Allarity Therapeutics Names Alexander Epshinsky CFO

Allarity Therapeutics Announces New CFO and Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Allarity Therapeutics Announces New CFO and Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Allarity Therapeutics Takes Decisive Step Toward Regaining Nasdaq Compliance with Nasdaq Listing Rule 5550(a)(2)

GlobeNewswire

a year ago

Allarity Therapeutics Takes Decisive Step Toward Regaining Nasdaq Compliance with Nasdaq Listing Rule 5550(a)(2)

MT Newswires

a year ago

Allarity Therapeutics to Implement 1-for-30 Reverse Stock Split; Shares Fall

MT Newswires

a year ago

Allarity Therapeutics' Shareholders to Sell 18.5 Million Shares

Allarity Therapeutics Announces Postponement of Annual Stockholders Meeting

GlobeNewswire

a year ago

Allarity Therapeutics Announces Postponement of Annual Stockholders Meeting

Allarity Encourages Shareholders to Vote FOR the Reverse Stock Split and Decrease in Authorized Shares

GlobeNewswire

a year ago

Allarity Encourages Shareholders to Vote FOR the Reverse Stock Split and Decrease in Authorized Shares

Allarity Therapeutics Outlines Company’s 2024 Progress and Objectives

GlobeNewswire

a year ago

Allarity Therapeutics Outlines Company’s 2024 Progress and Objectives

Allarity Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance

GlobeNewswire

a year ago

Allarity Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance

Allarity Therapeutics’ Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer

GlobeNewswire

a year ago

Allarity Therapeutics’ Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer

Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement

GlobeNewswire

a year ago

Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement

Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances

GlobeNewswire

a year ago

Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances

All You Need to Know About Allarity Therapeutics, Inc. (ALLR) Rating Upgrade to Buy

Zacks

a year ago

All You Need to Know About Allarity Therapeutics, Inc. (ALLR) Rating Upgrade to Buy

Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock

GlobeNewswire

a year ago

Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock

MT Newswires

a year ago

Allarity Therapeutics Says Stockholders' Equity 'Significantly' Exceeds Nasdaq's $2.5 Million Minimum Rule

Allarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1

GlobeNewswire

a year ago

Allarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1

Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer

GlobeNewswire

a year ago

Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer

Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement

GlobeNewswire

a year ago

Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement

Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)

GlobeNewswire

a year ago

Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)

Allarity Therapeutics Announces 1-for-20 Reverse Stock Split

GlobeNewswire

a year ago

Allarity Therapeutics Announces 1-for-20 Reverse Stock Split

Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer

GlobeNewswire

a year ago

Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer

Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)

GlobeNewswire

a year ago

Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)

Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update

GlobeNewswire

a year ago

Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update

Allarity Therapeutics to Present at Biomarkers 2024

GlobeNewswire

a year ago

Allarity Therapeutics to Present at Biomarkers 2024

OneMedNet Announces Participation as an Exhibitor at the 15ᵗʰ Annual SCOPE Summit

GlobeNewswire

2 years ago

OneMedNet Announces Participation as an Exhibitor at the 15ᵗʰ Annual SCOPE Summit

CFSB BANCORP, INC. ANNOUNCES FISCAL SECOND QUARTER AND YEAR-TO-DATE 2024 FINANCIAL RESULTS

PR Newswire

2 years ago

CFSB BANCORP, INC. ANNOUNCES FISCAL SECOND QUARTER AND YEAR-TO-DATE 2024 FINANCIAL RESULTS

MoneyHero Group Preannounces Record Breaking Year-Over-Year Growth, Outshining Competitors

GlobeNewswire

2 years ago

MoneyHero Group Preannounces Record Breaking Year-Over-Year Growth, Outshining Competitors

Modular Medical Announces Issuance of New US Patent

ACCESSWIRE

2 years ago

Modular Medical Announces Issuance of New US Patent

Aware Adds Product Strategy Innovator to Executive Team to Further Align Biometric Platform and Vision with Market Growth

GlobeNewswire

2 years ago

Aware Adds Product Strategy Innovator to Executive Team to Further Align Biometric Platform and Vision with Market Growth

Unicycive Therapeutics Issues Shareholder Letter to Highlight Corporate Progress and Key Upcoming Milestones

GlobeNewswire

2 years ago

Unicycive Therapeutics Issues Shareholder Letter to Highlight Corporate Progress and Key Upcoming Milestones

LifeVantage to Announce Second Quarter Fiscal Year 2024 Results on January 30, 2024

GlobeNewswire

2 years ago

LifeVantage to Announce Second Quarter Fiscal Year 2024 Results on January 30, 2024

4 Solid Stocks to Buy on Jump in Online Grocery Sales

Zacks

2 years ago

4 Solid Stocks to Buy on Jump in Online Grocery Sales

Save Foods: Nitrousink Files US Patent Application for Reducing Emissions of Nitrous Oxide in Wheat

GlobeNewswire

2 years ago

Save Foods: Nitrousink Files US Patent Application for Reducing Emissions of Nitrous Oxide in Wheat

Seth Klarman's Exit from Atara Biotherapeutics Inc

GuruFocus.com

2 years ago

Seth Klarman's Exit from Atara Biotherapeutics Inc

Seth Klarman's Firm Exits Atara Biotherapeutics Inc Holding

GuruFocus.com

2 years ago

Seth Klarman's Firm Exits Atara Biotherapeutics Inc Holding

Brera Holdings PLC Announces Six-Month Financial Results, Active Search for Italian Serie B Football Club Target

GlobeNewswire

2 years ago

Brera Holdings PLC Announces Six-Month Financial Results, Active Search for Italian Serie B Football Club Target

New to The Street Announces its Four Corporate Interviews, Episode 543, Airing on the Fox Business Network, Monday, January 8, 2024, at 10:30 PM PT

GlobeNewswire

2 years ago

New to The Street Announces its Four Corporate Interviews, Episode 543, Airing on the Fox Business Network, Monday, January 8, 2024, at 10:30 PM PT

Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID

GlobeNewswire

2 years ago

Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID

Chicken Soup for the Soul Entertainment, Inc. (CSSE) Reports Q3 Loss, Lags Revenue Estimates

Zacks

2 years ago

Chicken Soup for the Soul Entertainment, Inc. (CSSE) Reports Q3 Loss, Lags Revenue Estimates

enGene Announces Expanded $50 Million Debt Facility with Hercules Capital

CNW Group

2 years ago

enGene Announces Expanded $50 Million Debt Facility with Hercules Capital

Sentage Holdings Inc. Announces Financial Results for the First Six Months of Fiscal Year 2023

PR Newswire

2 years ago

Sentage Holdings Inc. Announces Financial Results for the First Six Months of Fiscal Year 2023

Know Labs, Inc. Reports Fourth Quarter and Fiscal Year 2023 Results

Business Wire

2 years ago

Know Labs, Inc. Reports Fourth Quarter and Fiscal Year 2023 Results

Nisun International Reports Unaudited Financial Results for the First Half of 2023

PR Newswire

2 years ago

Nisun International Reports Unaudited Financial Results for the First Half of 2023

Plus Updates Financial and Cash Guidance for 2024

GlobeNewswire

2 years ago

Plus Updates Financial and Cash Guidance for 2024

Know Labs Expands Medical and Scientific Advisory Board

Business Wire

2 years ago

Know Labs Expands Medical and Scientific Advisory Board

Clean Energy Announces Up to $400 Million in Financing with Stonepeak to Continue Expansion of Renewable Natural Gas Infrastructure

Business Wire

2 years ago

Clean Energy Announces Up to $400 Million in Financing with Stonepeak to Continue Expansion of Renewable Natural Gas Infrastructure

Allarity Therapeutics Announces Thomas Jensen as Interim CEO and Appointment of Jeremy R. Graff, PhD as Key Executive Advisor

GlobeNewswire

2 years ago

Allarity Therapeutics Announces Thomas Jensen as Interim CEO and Appointment of Jeremy R. Graff, PhD as Key Executive Advisor

Vivos Therapeutics Presents Groundbreaking Event: “Empowering Women to Champion Airway”

GlobeNewswire

2 years ago

Vivos Therapeutics Presents Groundbreaking Event: “Empowering Women to Champion Airway”

Here's Why Rubicon Technologies, Inc. (RBT) Is a Great 'Buy the Bottom' Stock Now

Zacks

2 years ago

Here's Why Rubicon Technologies, Inc. (RBT) Is a Great 'Buy the Bottom' Stock Now

ALLR: Stenoparib Clinical Update

Zacks Small Cap Research

2 years ago

ALLR: Stenoparib Clinical Update

Allarity’s Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP® Companion Diagnostic

GlobeNewswire

2 years ago

Allarity’s Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP® Companion Diagnostic

Vicinity Motor Corp. Announces Inclusion of VMC 1200 in Quebec Transportation Ministry's Incentive Program for Electric Vehicles

ACCESSWIRE

2 years ago

Vicinity Motor Corp. Announces Inclusion of VMC 1200 in Quebec Transportation Ministry's Incentive Program for Electric Vehicles

Coeptis Therapeutics to Present at the Emerging Growth Conference

PR Newswire

2 years ago

Coeptis Therapeutics to Present at the Emerging Growth Conference

PR Newswire

2 years ago

MIRA Pharmaceuticals Announces Ketamir-2's Oral Bioavailability Predicted to be 80%

BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval

GlobeNewswire

2 years ago

BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval

Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit

GlobeNewswire

2 years ago

Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

Business Wire

2 years ago

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

ALPHA PRO TECH, LTD. ANNOUNCES $2 MILLION EXPANSION OF SHARE REPURCHASE PROGRAM

GlobeNewswire

2 years ago

ALPHA PRO TECH, LTD. ANNOUNCES $2 MILLION EXPANSION OF SHARE REPURCHASE PROGRAM

MIRA Makes Great Deal for Potential Blockbuster

Zacks Small Cap Research

2 years ago

MIRA Makes Great Deal for Potential Blockbuster

PR Newswire

2 years ago

MIRA Pharmaceuticals To Host Shareholder Update Call on Tuesday, December 5, 2023 at 11:30 a.m. Eastern Time

PR Newswire

2 years ago

MIRA Pharmaceuticals Announces Paradigm-Shift in Cognitive Enhancement with MIRA1a

System1’s RoadWarrior App Introduces New Proof of Delivery for Packages, Launches New Marketplace for Subscription Add-Ons

Business Wire

2 years ago

System1’s RoadWarrior App Introduces New Proof of Delivery for Packages, Launches New Marketplace for Subscription Add-Ons

Presto Welcomes Industry Luminary Stephen Herbert as a Strategic Advisor for Presto Touch

GlobeNewswire

2 years ago

Presto Welcomes Industry Luminary Stephen Herbert as a Strategic Advisor for Presto Touch

BrainStorm Cell Therapeutics Announces In-Person Meeting with the FDA to Discuss Confirmatory Phase 3 Trial for NurOwn® in ALS

PR Newswire

2 years ago

BrainStorm Cell Therapeutics Announces In-Person Meeting with the FDA to Discuss Confirmatory Phase 3 Trial for NurOwn® in ALS

PR Newswire

2 years ago

MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2

HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus

GlobeNewswire

2 years ago

HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus

After Leaping 83% Ondas Holdings Inc. (NASDAQ:ONDS) Shares Are Not Flying Under The Radar

Simply Wall St.

2 years ago

After Leaping 83% Ondas Holdings Inc. (NASDAQ:ONDS) Shares Are Not Flying Under The Radar

Business Wire

2 years ago

PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc.

Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech

GlobeNewswire

2 years ago

Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech

UCloudlink Group Inc. Sponsored ADR (UCL) Beats Q3 Earnings and Revenue Estimates

Zacks

2 years ago

UCloudlink Group Inc. Sponsored ADR (UCL) Beats Q3 Earnings and Revenue Estimates

CXApp Inc. (NASDAQ:CXAI) Announces Q3 2023 Financial Results: Record Growth & Industry Momentum for CXAI Platform

ACCESSWIRE

2 years ago

CXApp Inc. (NASDAQ:CXAI) Announces Q3 2023 Financial Results: Record Growth & Industry Momentum for CXAI Platform

Precision Optics Reports First Quarter Fiscal Year 2024 Financial Results

PR Newswire

2 years ago

Precision Optics Reports First Quarter Fiscal Year 2024 Financial Results

Zacks Small Cap Research

2 years ago

MIRA Continues to Pursue New Pain Relief

Upexi Preannounces Revenue of $27.3 Million for Fiscal 2024 First Quarter and Reschedules Financial Results Conference Call for November 20th at 4:30 PM ET

ACCESSWIRE

2 years ago

Upexi Preannounces Revenue of $27.3 Million for Fiscal 2024 First Quarter and Reschedules Financial Results Conference Call for November 20th at 4:30 PM ET

Siebert Reports Third Quarter 2023 Financial Results

Business Wire

2 years ago

Siebert Reports Third Quarter 2023 Financial Results

Share on Social Networks: